Research

Hormonal

GLP-1 receptor agonists (exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide) effectively lower hemoglobin A1C and promote weight loss in patients with type 2 diabetes, offering advantages over sulfonylureas, thiazolidinediones, and insulin regarding weight gain and hypoglycemia risk.

If you have type 2 diabetes and struggle with weight gain or hypoglycemia from other meds, GLP-1 agonists are a strong option. They help lower blood sugar and promote weight loss. Start with a low dose to avoid stomach issues, and consider once-weekly versions if you dislike daily injections. Always combine with diet and exercise.

GoodSupportsHIGH confidence
GLP-1 receptor agonists represent a unique approach to the treatment of diabetes, with benefits extending outside glucose control, including positive effects on weight, blood pressure, cholesterol levels, and beta-cell function... The most common adverse effects seen with GLP-1 therapy include nausea, vomiting, and injection-site reactions.
Lalita Prasad‐Reddy et al. · Drugs in Context · 2015

Why this rating

The paper is a clinical review citing multiple randomized controlled trials (RCTs) and phase 3 studies (e.g., LEAD-6, AWARD studies).

Source

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond

Lalita Prasad‐Reddy et al. · Drugs in Context · 2015

DOI 10.7573/dic.212283

narrative_reviewCited 357×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →